University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers
March 06 2023 - 9:00AM
Business Wire
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company
and the leader in data-driven medicine, today announced the
University of Arkansas for Medical Sciences (UAMS), based in Little
Rock, AR, will use SOPHiA GENETICS’ platform to support their
clinical oncology research. Beginning this year, UAMS will
implement the SOPHiA DDM™ platform to gain deeper insights into
hematologic malignancies.
As the only health sciences university in the state of Arkansas
and the state’s largest public employer, UAMS is a cornerstone of
medical research and treatment for the state. SOPHiA DDM™ is a
cloud-based platform that uses Artificial Intelligence with
patented technologies and methods to synthesize next generation
sequencing (NGS) data. Such synthesis is key to identifying
characterizations of disease-causing mutations.
“Our mission at SOPHiA GENETICS is to democratize data-driven
medicine, making it more accessible to all,” said Ken Freedman,
Chief Revenue Officer, SOPHiA GENETICS. “The adoption of SOPHiA
DDM™ for UAMS – Arkansas’ only health sciences university – will
benefit the entire state and larger medical community by providing
the institution with more comprehensive insights from their
data.”
Hematologic malignancies such as leukemia, lymphoma, or plasma
cell myeloma can move fast. Clinical researchers need to be able to
move quickly as well. Having the ability to synthesize NGS data
in-house builds local expertise and allows for faster data
turnaround, a benefit to both clinical researchers and
patients.
Hematological tumors represent the fourth most frequent cancer
type in the developed world.1 The SOPHiA DDM™ for Blood Cancers
solution is designed to accelerate and streamline the analyses of
blood cancers and positively impact disease management.
“We’re excited to bring this technology to the state of
Arkansas,” said Philippe Menu, Chief Medical Officer, SOPHiA
GENETICS. “One person in the U.S. is diagnosed with leukemia,
lymphoma, or myeloma roughly every three minutes2. The SOPHiA DDM™
for Blood Cancers solution will put increased data at the
fingertips of clinical researchers.”
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn,
Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook, and Instagram.
Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management’s beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
About UAMS
UAMS is the state's only health sciences university, with
colleges of Medicine, Nursing, Pharmacy, Health Professions and
Public Health; a graduate school; a hospital; a main campus in
Little Rock; a Northwest Arkansas regional campus in Fayetteville;
a statewide network of regional campuses; and seven institutes: the
Winthrop P. Rockefeller Cancer Institute, Jackson T. Stephens Spine
& Neurosciences Institute, Harvey & Bernice Jones Eye
Institute, Psychiatric Research Institute, Donald W. Reynolds
Institute on Aging, Translational Research Institute and Institute
for Digital Health & Innovation. UAMS includes UAMS Health, a
statewide health system that encompasses all of UAMS' clinical
enterprise. UAMS is the only adult Level 1 trauma center in the
state. UAMS has 3,240 students, 913 medical residents and fellows,
and five dental residents. It is the state's largest public
employer with more than 11,000 employees, including 1,200
physicians who provide care to patients at UAMS, its regional
campuses, Arkansas Children's, the VA Medical Center and Baptist
Health. Visit www.uams.edu or uamshealth.com. Find us on Facebook,
Twitter, YouTube or Instagram.
1 https://gco.iarc.fr/today/fact-sheets-cancers accessed on May
19th, 2021.
2
https://www.lls.org/facts-and-statistics/facts-and-statistics-overview#:~:text=Approximately%20every%209%20minutes%2C%20someone,than%20six%20people%20every%20hour.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230306005157/en/
Media: Nick Puleo npuleo@comsint.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024